Advanced search
1 file | 924.43 KB Add to list

Validation of postinduction Curie scores in high-risk neuroblastoma : a Children's Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1

(2018) JOURNAL OF NUCLEAR MEDICINE. 59(3). p.502-508
Author
Organization
Abstract
A semiquantitative I-123-metaiodobenzylguanidine (I-123-MIBG) scoring method (the Curie score, or CS) was previously examined in the Children's Oncology Group (COG) high-risk neuroblastoma trial, COG A3973, with a postinduction CS of more than 2 being associated with poor event-free survival (EFS). The validation of the CS in an independent dataset, International Society of Paediatric Oncology European Neuroblastoma/High-Risk Neuroblastoma 1 (SIOPEN/HR-NBL1), is now reported. Methods: A retrospective analysis of I-123-MIBG scans obtained from patients who had been prospectively enrolled in SIOPEN/HR-NBL1 was performed. All patients exhibited I-123-MIBG-avid, International Neuroblastoma Staging System stage 4 neuroblastoma. I-123-MIBG scans were evaluated at 2 time points, diagnosis (n = 345) and postinduction (n = 330), before consolidation myeloablative therapy. Scans of 10 anatomic regions were evaluated, with each region being scored 0-3 on the basis of disease extent and a cumulative CS generated. Cut points for outcome analysis were identified by Youden methodology. CSs from patients enrolled in COG A3973 were used for comparison. Results: The optimal cut point for CS at diagnosis was 12 in SIOPEN/HR-NBL1, with a significant outcome difference by CS noted (5-y EFS, 43.0% +/- 5.7% [CS <= 12] vs. 21.4% +/- 3.6% [CS > 12], P, 0.0001). The optimal CS cut point after induction was 2 in SIOPEN/HR-NBL1, with a postinduction CS of more than 2 being associated with an inferior outcome (5-y EFS, 39.2% +/- 4.7%[CS <= 2] vs. 16.4% +/- 4.2%[CS > 2], P< 0.0001). The postinduction CS maintained independent statistical significance in Cox models when adjusted for the covariates of age and MYCN gene copy number. Conclusion: The prognostic significance of postinduction CSs has now been validated in an independent cohort of patients (SIOPEN/HR-NBL1), with a postinduction CS of more than 2 being associated with an inferior outcome in 2 independent large, cooperative group trials.
Keywords
neuroblastoma, MIBG, Curie score, STAGE-IV NEUROBLASTOMA, EVENT-FREE SURVIVAL, INDUCTION CHEMOTHERAPY, RANDOMIZED-TRIAL, METAIODOBENZYLGUANIDINE SCINTIGRAPHY, METASTATIC NEUROBLASTOMA, SCORING SYSTEM, PHASE-3 TRIAL, MIBG, IMPACT

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 924.43 KB

Citation

Please use this url to cite or link to this publication:

MLA
Yanik, Gregory A, Marguerite T Parisi, Arlene Naranjo, et al. “Validation of Postinduction Curie Scores in High-risk Neuroblastoma : a Children’s Oncology Group (COG) and SIOPEN Group Report on SIOPEN/HR-NBL1.” JOURNAL OF NUCLEAR MEDICINE 59.3 (2018): 502–508. Print.
APA
Yanik, G. A., Parisi, M. T., Naranjo, A., Nadel, H., Gelfand, M. J., Park, J. R., Ladenstein, R. L., et al. (2018). Validation of postinduction Curie scores in high-risk neuroblastoma : a Children’s Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1. JOURNAL OF NUCLEAR MEDICINE, 59(3), 502–508.
Chicago author-date
Yanik, Gregory A, Marguerite T Parisi, Arlene Naranjo, Helen Nadel, Michael J Gelfand, Julie R Park, Ruth L Ladenstein, et al. 2018. “Validation of Postinduction Curie Scores in High-risk Neuroblastoma : a Children’s Oncology Group (COG) and SIOPEN Group Report on SIOPEN/HR-NBL1.” Journal of Nuclear Medicine 59 (3): 502–508.
Chicago author-date (all authors)
Yanik, Gregory A, Marguerite T Parisi, Arlene Naranjo, Helen Nadel, Michael J Gelfand, Julie R Park, Ruth L Ladenstein, Ulrike Poetschger, Ariane Boubaker, Dominique Valteau-Couanet, Bieke Lambert, Maria-Rita Castellani, Zvi Bar-Sever, Aurore Oudoux, Anna Kaminska, Susan G Kreissman, Barry L Shulkin, and Katherine K Matthay. 2018. “Validation of Postinduction Curie Scores in High-risk Neuroblastoma : a Children’s Oncology Group (COG) and SIOPEN Group Report on SIOPEN/HR-NBL1.” Journal of Nuclear Medicine 59 (3): 502–508.
Vancouver
1.
Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, et al. Validation of postinduction Curie scores in high-risk neuroblastoma : a Children’s Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1. JOURNAL OF NUCLEAR MEDICINE. 2018;59(3):502–8.
IEEE
[1]
G. A. Yanik et al., “Validation of postinduction Curie scores in high-risk neuroblastoma : a Children’s Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1,” JOURNAL OF NUCLEAR MEDICINE, vol. 59, no. 3, pp. 502–508, 2018.
@article{8531329,
  abstract     = {A semiquantitative I-123-metaiodobenzylguanidine (I-123-MIBG) scoring method (the Curie score, or CS) was previously examined in the Children's Oncology Group (COG) high-risk neuroblastoma trial, COG A3973, with a postinduction CS of more than 2 being associated with poor event-free survival (EFS). The validation of the CS in an independent dataset, International Society of Paediatric Oncology European Neuroblastoma/High-Risk Neuroblastoma 1 (SIOPEN/HR-NBL1), is now reported. Methods: A retrospective analysis of I-123-MIBG scans obtained from patients who had been prospectively enrolled in SIOPEN/HR-NBL1 was performed. All patients exhibited I-123-MIBG-avid, International Neuroblastoma Staging System stage 4 neuroblastoma. I-123-MIBG scans were evaluated at 2 time points, diagnosis (n = 345) and postinduction (n = 330), before consolidation myeloablative therapy. Scans of 10 anatomic regions were evaluated, with each region being scored 0-3 on the basis of disease extent and a cumulative CS generated. Cut points for outcome analysis were identified by Youden methodology. CSs from patients enrolled in COG A3973 were used for comparison. Results: The optimal cut point for CS at diagnosis was 12 in SIOPEN/HR-NBL1, with a significant outcome difference by CS noted (5-y EFS, 43.0% +/- 5.7% [CS <= 12] vs. 21.4% +/- 3.6% [CS > 12], P, 0.0001). The optimal CS cut point after induction was 2 in SIOPEN/HR-NBL1, with a postinduction CS of more than 2 being associated with an inferior outcome (5-y EFS, 39.2% +/- 4.7%[CS <= 2] vs. 16.4% +/- 4.2%[CS > 2], P< 0.0001). The postinduction CS maintained independent statistical significance in Cox models when adjusted for the covariates of age and MYCN gene copy number. Conclusion: The prognostic significance of postinduction CSs has now been validated in an independent cohort of patients (SIOPEN/HR-NBL1), with a postinduction CS of more than 2 being associated with an inferior outcome in 2 independent large, cooperative group trials.},
  author       = {Yanik, Gregory A and Parisi, Marguerite T and Naranjo, Arlene and Nadel, Helen and Gelfand, Michael J and Park, Julie R and Ladenstein, Ruth L and Poetschger, Ulrike and Boubaker, Ariane and Valteau-Couanet, Dominique and Lambert, Bieke and Castellani, Maria-Rita and Bar-Sever, Zvi and Oudoux, Aurore and Kaminska, Anna and Kreissman, Susan G and Shulkin, Barry L and Matthay, Katherine K},
  issn         = {0161-5505},
  journal      = {JOURNAL OF NUCLEAR MEDICINE},
  keywords     = {neuroblastoma,MIBG,Curie score,STAGE-IV NEUROBLASTOMA,EVENT-FREE SURVIVAL,INDUCTION CHEMOTHERAPY,RANDOMIZED-TRIAL,METAIODOBENZYLGUANIDINE SCINTIGRAPHY,METASTATIC NEUROBLASTOMA,SCORING SYSTEM,PHASE-3 TRIAL,MIBG,IMPACT},
  language     = {eng},
  number       = {3},
  pages        = {502--508},
  title        = {Validation of postinduction Curie scores in high-risk neuroblastoma : a Children's Oncology Group (COG) and SIOPEN group report on SIOPEN/HR-NBL1},
  url          = {http://dx.doi.org/10.2967/jnumed.117.195883},
  volume       = {59},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: